ADAR1 Capital Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), ADAR1 Capital Management, LLC reported 223 stock positions worth $366.2 million. Its top holding was Alpha Architect 1-3 MNTH Box (BOXX) at 9.2% of the portfolio, followed by Roivant Sciences (ROIV, 8.0%) and Alnylam Pharmaceuticals (ALNY, 7.4%). Compared with Q4 2023, it opened 119 new positions, sold out of 28, added to 35 and reduced 44. The biggest buy was a new position in Alpha Architect 1-3 MNTH Box (BOXX) and the biggest sale Royalty Pharma Class A (RPRX, shares −45%).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001940272
- Portfolio Value
- $366.2M (Q1 2024)
- SEC Filing
- 0001940272-24-000003 ↗ filed May 15, 2024
Holdings Value
Holdings 223 stocks · $366.2M
| BOXX Alpha Architect 1-3 MNTH Box | 9.25% | 318,120 | $33.9M | New |
| ROIV Roivant Sciences Ltd. | 8.03% | 2,791,870 | $29.4M | Add +122.2% |
| ALNY Alnylam Pharmaceuticals Inc. | 7.35% | 180,145 | $26.9M | Add +1796.3% |
| PTGX Protagonist Therapeutics Inc. | 6.21% | 785,655 | $22.7M | Add +291.1% |
| CYTK Cytokinetics Inc. | 6.12% | 319,510 | $22.4M | Add +247.0% |
| KROS Keros Therapeutics Inc. | 6.11% | 338,243 | $22.4M | Reduce -50.9% |
| RPRX Royalty Pharma PLC Class A | 5.98% | 721,301 | $21.9M | Reduce -45.4% |
| BBIO Bridgebio Pharma Inc. | 4.64% | 549,804 | $17.0M | Add +197.0% |
| MACK Merrimack Pharmaceuticals Inc. | 3.64% | 902,350 | $13.3M | Add +64.2% |
| ASND Ascendis Pharma A/S | 2.01% | 48,584 | $7.3M | Add +5.9% |
| ABUS Arbutus Biopharma Corp. | 1.46% | 2,074,183 | $5.4M | Reduce -40.2% |
| AVROBIO INC | 1.38% | 3,954,857 | $5.1M | Add +7786.5% |
| ONC Beone Medicines Ltd.-ADR filed as BEIGENE LTD | 1.35% | 31,505 | $4.9M | Add +1453.5% |
| ALKS Alkermes PLC | 1.16% | 156,600 | $4.2M | New |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 1.15% | 403,500 | $4.2M | New |
| SRPT Sarepta Therapeutics Inc. | 1.10% | 31,105 | $4.0M | Add +285.8% |
| EDR Endeavor Group Hold Class A | 1.09% | 155,250 | $4.0M | Add +6110.0% |
| ACHV Achieve Life Sciences Inc. | 1.09% | 875,000 | $4.0M | New |
| FUSN Fusion Pharmaceuticals Inc. | 1.03% | 177,200 | $3.8M | New |
| ABSI Absci Corp. | 0.91% | 586,984 | $3.3M | New |
| EWTX Edgewise Therapeutics Inc. | 0.90% | 180,911 | $3.3M | New |
| FULC Fulcrum Therapeutics Inc. | 0.88% | 339,825 | $3.2M | Reduce -46.7% |
| QTTB Q32 Bio Inc. | 0.87% | 187,567 | $3.2M | New |
| APLT Applied Therapeutics Inc. | 0.85% | 456,588 | $3.1M | New |
| BIL SS SPDR BB 1-3M T-Bill ETF | 0.81% | 32,500 | $3.0M | Add +1.6% |
| PFE Pfizer Inc. | 0.81% | 106,342 | $3.0M | Add +511.2% |
| VUSB Vanguard Ultra Short Bond Et | 0.75% | 55,206 | $2.7M | Add +10.0% |
| JPST JPMorgan Ultra-Short Income | 0.74% | 54,000 | $2.7M | Add +10.2% |
| SHV iShares 0-1 Year Treasury Bo | 0.74% | 24,500 | $2.7M | No change |
| SLDB Solid Biosciences Inc. | 0.74% | 203,204 | $2.7M | Add +20220.4% |
| USFR Wisdomtree Floating Rate Tre | 0.73% | 53,000 | $2.7M | Reduce -5.4% |
| CLRB Cellectar Biosciences Inc. | 0.70% | 642,541 | $2.6M | Reduce -53.4% |
| OABI Omniab Inc. | 0.67% | 451,485 | $2.4M | Reduce -5.6% |
| CNTA Centessa Pharmaceuticals Ltd. | 0.64% | 206,856 | $2.3M | New |
| REGN Regeneron Pharmaceuticals | 0.60% | 2,300 | $2.2M | New |
| IBIO Ibio Inc. | 0.60% | 600,000 | $2.2M | New |
| CTVA Corteva Inc. | 0.59% | 37,400 | $2.2M | Reduce -35.5% |
| XAIR Beyond Air Inc. | 0.57% | 1,204,820 | $2.1M | New |
| IMVT Immunovant Inc. | 0.54% | 60,763 | $2.0M | Reduce -54.7% |
| LGND Ligand Pharmaceuticals | 0.53% | 26,800 | $2.0M | New |
| ULST SS Ultra Short TM Bond ETF | 0.53% | 47,684 | $1.9M | Reduce -22.2% |
| SYRE Spyre Therapeutics Inc. | 0.51% | 49,500 | $1.9M | Add +668.6% |
| SDGR Schrodinger Inc. | 0.47% | 63,586 | $1.7M | Add +3079.3% |
| SPRO Spero Therapeutics Inc. | 0.44% | 926,929 | $1.6M | Reduce -13.2% |
| QURE Uniqure NV | 0.42% | 292,850 | $1.5M | New |
| APLS Apellis Pharmaceuticals Inc. | 0.41% | 25,700 | $1.5M | New |
| LLY Eli Lilly & Co. | 0.40% | 1,865 | $1.5M | New |
| TEVA Teva Pharmaceutical-SP ADR | 0.39% | 101,626 | $1.4M | Reduce -8.7% |
| NGM NGM Biopharmaceuticals Inc. | 0.35% | 816,581 | $1.3M | New |
| VKTX Viking Therapeutics Inc. | 0.32% | 14,401 | $1.2M | Reduce -94.3% |
| KNSA Kiniksa Pharmaceuticals Ltd. | 0.32% | 59,700 | $1.2M | Reduce -43.1% |
| NVNO Envveno Medical Corporation | 0.30% | 201,728 | $1.1M | New |
| ARVN Arvinas Inc. | 0.30% | 26,200 | $1.1M | New |
| DCTH Delcath Systems Inc. | 0.29% | 218,973 | $1.0M | Reduce -5.3% |
| CERE Cerevel Therapeutics Holding | 0.28% | 24,259 | $1.0M | Reduce -78.1% |
| ANGO Angiodynamics Inc. | 0.25% | 153,362 | $900K | Add +15.3% |
| SLN Silence Therapeutics PLC-ADR | 0.24% | 40,090 | $866K | Add +21000.0% |
| GOSS Gossamer Bio Inc. | 0.24% | 732,628 | $865K | Add +2.8% |
| GLST Global Star Acquisition Class A | 0.23% | 80,000 | $857K | No change |
| VYGR Voyager Therapeutics Inc. | 0.23% | 91,534 | $852K | Reduce -50.8% |
| CATX Perspective Therapeutics Inc. | 0.22% | 676,725 | $805K | Add +1503.6% |
| KVAUF Keen Vision Acquisition Corp. | 0.22% | 75,000 | $788K | No change |
| ATNM Actinium Pharmaceuticals Inc. | 0.21% | 100,000 | $783K | New |
| KPRX Kiora Pharmaceuticals Inc. | 0.21% | 1,100,000 | $777K | New |
| ACASTI PHARMA INC | 0.20% | 217,381 | $745K | Add +529.5% |
| MORF Morphic Holding Inc. | 0.19% | 19,701 | $693K | New |
| KYMR Kymera Therapeutics Inc. | 0.18% | 16,000 | $643K | New |
| CRBP Corbus Pharmaceuticals Holdi | 0.17% | 16,000 | $628K | New |
| TXMD Therapeuticsmd Inc. | 0.17% | 272,160 | $623K | No change |
| WST West Pharmaceutical Services | 0.16% | 1,500 | $594K | New |
| INDV Indivior Ltd. | 0.16% | 27,601 | $591K | Add +14.5% |
| RYTM Rhythm Pharmaceuticals Inc. | 0.15% | 12,400 | $537K | New |
| TMTC TMT Acquisition Corp. Class A | 0.15% | 50,000 | $535K | No change |
| JANX Janux Therapeutics Inc. | 0.14% | 14,000 | $527K | New |
| NRIX Nurix Therapeutics Inc. | 0.14% | 35,608 | $523K | New |
| YEAR AB Ultra Short Income ETF filed as AB ACTIVE ETFS INC | 0.14% | 10,000 | $505K | No change |
| STVN Stevanato Group SPA | 0.14% | 15,500 | $498K | New |
| PULS Pgim Ultra Short Bond ETF | 0.14% | 10,000 | $497K | No change |
| VTGN Vistagen Therapeutics Inc. | 0.13% | 89,938 | $475K | Reduce -63.4% |
| AEROVATE THERAPEUTICS INC | 0.13% | 15,900 | $470K | New |
| TYRA Tyra Biosciences Inc. | 0.13% | 28,300 | $464K | New |
| ARYD Arya Sciences Acquisition-A | 0.13% | 40,930 | $460K | New |
| EQ Equillium Inc. | 0.13% | 198,775 | $459K | Add +2958.1% |
| INTELLIGENT BIO SOLUTIONS IN | 0.12% | 108,250 | $457K | New |
| APGE Apogee Therapeutics Inc. | 0.11% | 6,000 | $399K | New |
| MIST Milestone Pharmaceuticals Inc. | 0.10% | 202,460 | $362K | New |
| BCYC Bicycle Therapeutics PLC-ADR | 0.10% | 14,430 | $359K | Reduce -80.7% |
| ZLAB Zai Lab Ltd.-ADR | 0.10% | 22,000 | $352K | Add +10.0% |
| GH Guardant Health Inc. | 0.10% | 17,000 | $351K | New |
| VYNE THERAPEUTICS INC | 0.09% | 110,091 | $338K | New |
| CTMX Cytomx Therapeutics Inc. | 0.09% | 155,000 | $338K | New |
| OAKU Oak Woods Acquisition Corp. Class A | 0.09% | 30,000 | $323K | No change |
| SCRM Screaming Eagle Acq Class A | 0.09% | 30,000 | $321K | No change |
| ALEC Alector Inc. | 0.09% | 52,500 | $316K | New |
| MLYS Mineralys Therapeutics Inc. | 0.08% | 24,000 | $310K | New |
| JVSAU Jvspac Acquisition Corp. | 0.08% | 30,000 | $309K | New |
| GOOGL Alphabet Inc. Class A | 0.08% | 2,000 | $302K | New |
| SPRB Spruce Biosciences Inc. | 0.08% | 365,216 | $287K | New |
| CNTX Context Therapeutics Inc. | 0.08% | 205,934 | $284K | New |
| SNY Sanofi-ADR | 0.07% | 5,500 | $267K | New |
Options reported separately and not counted above: ALNY puts ($35.0M), SPY puts ($27.2M), QQQ puts ($4.4M), CERE puts ($2.1M), GH calls ($2.1M), ALNY calls ($1.7M), GLYCOMIMETICS INC puts ($417K), DJT calls ($279K), AMLX calls ($210K), APLT puts ($205K), CYTK calls ($175K), SRPT calls ($155K), and 10 more.
Other holdings (16): bonds, preferreds, convertibles and warrants · $37K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| GLSTR Global Star Acquisition-RTS | RIGHT 99/99/9999 | 118,400 | $11K | No change |
| TMTCR TMT Acquisition Corp.-RT | RIGHT 03/27/2028 | 49,900 | $9K | No change |
| OAKUR Oak Woods Acquisition Cor-RT | RIGHT 03/23/2028 | 30,000 | $6K | No change |
| EMCRF Embrace Change Acq-Rights | RIGHT 10/25/2026 | 18,000 | $3K | No change |
| GLSTW Global Star Acquisition-27 A | *W EXP 07/15/202 | 120,000 | $2K | No change |
| FLFVR Feutune Light Acquisitio-RTS | RIGHT 06/01/2029 | 15,000 | $1K | No change |
| FTIIW Futuretech II Acq -CW27 | *W EXP 08/18/202 | 30,000 | $1K | No change |
| ECD AUTOMOTIVE DESIGN INC | *W EXP 12/12/202 | 32,596 | $818 | No change |
| SBCWW Pono Capital Two Inc. -27 | *W EXP 09/17/202 | 19,800 | $693 | No change |
| CETUR Cetus Capital Acquisition Co. | RIGHT 03/31/2024 | 4,999 | $605 | No change |
| OAKUW Oak Woods Acquisition -28 | *W EXP 99/99/999 | 30,000 | $600 | No change |
| FLFVW Feutune Light Acquisit -29 | *W EXP 06/01/202 | 15,000 | $510 | No change |
| EMCWF Embrace Change Acquisitio-26 | *W EXP 10/25/202 | 18,000 | $407 | No change |
| FORLW Four Leaf Acquisition Cor-28 | *W EXP 03/15/202 | 9,487 | $390 | No change |
| AIMWF Aimfinity Investment-CW27 | *W EXP 99/99/999 | 18,000 | $234 | No change |
| CETUW Cetus Capital Acquisition-28 | *W EXP 01/31/202 | 5,000 | $95 | No change |
Total filed on the 13F, all lines: $366.3M.
Portfolio Sells Q4 2023 → Q1 2024
| RPRX Royalty Pharma PLC Class A | Reduce -45.4% | 5.98% | −10.65 |
| KROS Keros Therapeutics Inc. | Reduce -50.9% | 6.11% | −6.14 |
| MRTX Mirati Therapeutics Inc. | Sold out | 0.00% | −2.84 |
| MRK Merck & Co. Inc. | Reduce -99.4% | 0.01% | −2.63 |
| ABUS Arbutus Biopharma Corp. | Reduce -40.2% | 1.46% | −2.42 |
| IMVT Immunovant Inc. | Reduce -54.7% | 0.54% | −1.99 |
| CERE Cerevel Therapeutics Holding | Reduce -78.1% | 0.28% | −1.82 |
| VKTX Viking Therapeutics Inc. | Reduce -94.3% | 0.32% | −1.80 |
| KRTX Karuna Therapeutics Inc. | Sold out | 0.00% | −1.42 |
| AYX Alteryx Inc. Class A | Sold out | 0.00% | −1.31 |
| FULC Fulcrum Therapeutics Inc. | Reduce -46.7% | 0.88% | −1.05 |
| CLRB Cellectar Biosciences Inc. | Reduce -53.4% | 0.70% | −1.01 |
| IMGN Immunogen Inc. | Sold out | 0.00% | −0.85 |
| UTHR United Therapeutics Corp. | Sold out | 0.00% | −0.79 |
| CTVA Corteva Inc. | Reduce -35.5% | 0.59% | −0.66 |
| OABI Omniab Inc. | Reduce -5.6% | 0.67% | −0.65 |
| ATXS Astria Therapeutics Inc. | Reduce -97.6% | 0.02% | −0.64 |
| ULST SS Ultra Short TM Bond ETF | Reduce -22.2% | 0.53% | −0.58 |
| SHY iShares 1-3 Year Treasury Bo | Sold out | 0.00% | −0.55 |
| USFR Wisdomtree Floating Rate Tre | Reduce -5.4% | 0.73% | −0.53 |
| KVUE Kenvue Inc. | Sold out | 0.00% | −0.51 |
| BCYC Bicycle Therapeutics PLC-ADR | Reduce -80.7% | 0.10% | −0.51 |
| KNSA Kiniksa Pharmaceuticals Ltd. | Reduce -43.1% | 0.32% | −0.50 |
| AMLX Amylyx Pharmaceuticals Inc. | Reduce -49.9% | 0.03% | −0.48 |
| VYGR Voyager Therapeutics Inc. | Reduce -50.8% | 0.23% | −0.47 |
| ORTX Orchard Therapeutics Ltd. | Sold out | 0.00% | −0.47 |
| VTGN Vistagen Therapeutics Inc. | Reduce -63.4% | 0.13% | −0.44 |
| ARQT Arcutis Biotherapeutics Inc. | Reduce -98.5% | 0.01% | −0.39 |
| THRX Theseus Pharmaceuticals Inc. | Sold out | 0.00% | −0.32 |
| MRUS Merus NV | Sold out | 0.00% | −0.30 |
| NVO Novo-Nordisk A/S-Spons ADR | Reduce -98.4% | 0.00% | −0.29 |
| SPRO Spero Therapeutics Inc. | Reduce -13.2% | 0.44% | −0.27 |
| GOVT iShares US Treasury Bond ETF | Sold out | 0.00% | −0.21 |
| AKRO Akero Therapeutics Inc. | Reduce -88.7% | 0.01% | −0.15 |
| DCTH Delcath Systems Inc. | Reduce -5.3% | 0.29% | −0.15 |
| GHIX Gores Holding Ix Inc. Class A | Sold out | 0.00% | −0.14 |
| TSHA Taysha Gene Therapies Inc. | Reduce -79.2% | 0.03% | −0.13 |
| TEVA Teva Pharmaceutical-SP ADR | Reduce -8.7% | 0.39% | −0.13 |
| GLRE Greenlight Capital Re Ltd. Class A | Reduce -60.7% | 0.05% | −0.13 |
| RLMD Relmada Therapeutics Inc. | Reduce -99.0% | 0.00% | −0.11 |
| VERU Veru Inc. | Reduce -32.8% | 0.06% | −0.10 |
| HHH Howard Hughes Holdings Inc. | Reduce -66.7% | 0.02% | −0.10 |
| MO Altria Group Inc. | Reduce -66.7% | 0.02% | −0.08 |
| HOMOLOGY MEDICINES INC | Sold out | 0.00% | −0.08 |
| AQN Algonquin Power & Utilities | Reduce -26.0% | 0.06% | −0.08 |
| BUR Burford Capital Ltd. | Sold out | 0.00% | −0.07 |
| THC Tenet Healthcare Corp. | Sold out | 0.00% | −0.07 |
| ANIP Ani Pharmaceuticals Inc. | Sold out | 0.00% | −0.06 |
| PRTA Prothena Corp. PLC | Reduce -1.9% | 0.04% | −0.06 |
| IMTX Immatics NV | Reduce -26.4% | 0.05% | −0.06 |
Portfolio Buys Q4 2023 → Q1 2024
| BOXX Alpha Architect 1-3 MNTH Box | New | 9.25% | +9.25 |
| ALNY Alnylam Pharmaceuticals Inc. | Add +1796.3% | 7.35% | +6.54 |
| PTGX Protagonist Therapeutics Inc. | Add +291.1% | 6.21% | +4.14 |
| CYTK Cytokinetics Inc. | Add +247.0% | 6.12% | +2.67 |
| ROIV Roivant Sciences Ltd. | Add +122.2% | 8.03% | +1.72 |
| AVROBIO INC | Add +7786.5% | 1.38% | +1.35 |
| BBIO Bridgebio Pharma Inc. | Add +197.0% | 4.64% | +1.29 |
| ONC Beone Medicines Ltd.-ADR | Add +1453.5% | 1.35% | +1.18 |
| ALKS Alkermes PLC | New | 1.16% | +1.16 |
| BBOT Bridgebio Oncology Therapeut | New | 1.15% | +1.15 |
| ACHV Achieve Life Sciences Inc. | New | 1.09% | +1.09 |
| EDR Endeavor Group Hold Class A | Add +6110.0% | 1.09% | +1.06 |
| FUSN Fusion Pharmaceuticals Inc. | New | 1.03% | +1.03 |
| ABSI Absci Corp. | New | 0.91% | +0.91 |
| EWTX Edgewise Therapeutics Inc. | New | 0.90% | +0.90 |
| QTTB Q32 Bio Inc. | New | 0.87% | +0.87 |
| APLT Applied Therapeutics Inc. | New | 0.85% | +0.85 |
| SRPT Sarepta Therapeutics Inc. | Add +285.8% | 1.10% | +0.75 |
| SLDB Solid Biosciences Inc. | Add +20220.4% | 0.74% | +0.74 |
| CNTA Centessa Pharmaceuticals Ltd. | New | 0.64% | +0.64 |
| REGN Regeneron Pharmaceuticals | New | 0.60% | +0.60 |
| IBIO Ibio Inc. | New | 0.60% | +0.60 |
| PFE Pfizer Inc. | Add +511.2% | 0.81% | +0.58 |
| XAIR Beyond Air Inc. | New | 0.57% | +0.57 |
| LGND Ligand Pharmaceuticals | New | 0.53% | +0.53 |
| SYRE Spyre Therapeutics Inc. | Add +668.6% | 0.51% | +0.45 |
| SDGR Schrodinger Inc. | Add +3079.3% | 0.47% | +0.44 |
| QURE Uniqure NV | New | 0.42% | +0.42 |
| APLS Apellis Pharmaceuticals Inc. | New | 0.41% | +0.41 |
| LLY Eli Lilly & Co. | New | 0.40% | +0.40 |
| NGM NGM Biopharmaceuticals Inc. | New | 0.35% | +0.35 |
| MACK Merrimack Pharmaceuticals Inc. | Add +64.2% | 3.64% | +0.34 |
| NVNO Envveno Medical Corporation | New | 0.30% | +0.30 |
| ARVN Arvinas Inc. | New | 0.30% | +0.30 |
| SLN Silence Therapeutics PLC-ADR | Add +21000.0% | 0.24% | +0.23 |
| ATNM Actinium Pharmaceuticals Inc. | New | 0.21% | +0.21 |
| CATX Perspective Therapeutics Inc. | Add +1503.6% | 0.22% | +0.21 |
| KPRX Kiora Pharmaceuticals Inc. | New | 0.21% | +0.21 |
| MORF Morphic Holding Inc. | New | 0.19% | +0.19 |
| KYMR Kymera Therapeutics Inc. | New | 0.18% | +0.18 |
| CRBP Corbus Pharmaceuticals Holdi | New | 0.17% | +0.17 |
| WST West Pharmaceutical Services | New | 0.16% | +0.16 |
| ACASTI PHARMA INC | Add +529.5% | 0.20% | +0.16 |
| RYTM Rhythm Pharmaceuticals Inc. | New | 0.15% | +0.15 |
| JANX Janux Therapeutics Inc. | New | 0.14% | +0.14 |
| NRIX Nurix Therapeutics Inc. | New | 0.14% | +0.14 |
| STVN Stevanato Group SPA | New | 0.14% | +0.14 |
| AEROVATE THERAPEUTICS INC | New | 0.13% | +0.13 |
| TYRA Tyra Biosciences Inc. | New | 0.13% | +0.13 |
| ARYD Arya Sciences Acquisition-A | New | 0.13% | +0.13 |
Options Activity Q4 2023 → Q1 2024
| ALNY Alnylam Pharmaceuticals Inc. | put | Add +2.5% | 234,400 | $35.0M |
| SPY SS SPDR S&P 500 ETF Trust-US | put | New | 52,000 | $27.2M |
| QQQ Invesco QQQ Trust Series 1 | put | New | 10,000 | $4.4M |
| GH Guardant Health Inc. | call | New | 100,000 | $2.1M |
| ALNY Alnylam Pharmaceuticals Inc. | call | New | 11,200 | $1.7M |
| PFE Pfizer Inc. | call | Sold out | 43,000 | $1.2Mbefore exit |
| BCYC Bicycle Therapeutics PLC-ADR | put | Sold out | 54,100 | $978Kbefore exit |
| ABUS Arbutus Biopharma Corp. | call | Sold out | 177,700 | $444Kbefore exit |
| GLYCOMIMETICS INC | put | New | 139,100 | $417K |
| CYTK Cytokinetics Inc. | put | Sold out | 3,500 | $292Kbefore exit |
| DJT Trump Media & Technology Gro | call | New | 4,500 | $279K |
| AMLX Amylyx Pharmaceuticals Inc. | call | Add +517.5% | 74,100 | $210K |
| APLT Applied Therapeutics Inc. | put | New | 30,100 | $205K |
| CYTK Cytokinetics Inc. | call | Reduce -96.6% | 2,500 | $175K |
| SRPT Sarepta Therapeutics Inc. | call | New | 1,200 | $155K |
| MDGL Madrigal Pharmaceuticals Inc. | put | Sold out | 500 | $116Kbefore exit |
| BHVN Biohaven Ltd. | call | New | 2,000 | $109K |
| BHC Bausch Health Cos Inc. | call | New | 6,000 | $64K |
| IMGN Immunogen Inc. | call | Sold out | 2,000 | $59Kbefore exit |
| INSM Insmed Inc. | put | New | 1,700 | $46K |
| RYTM Rhythm Pharmaceuticals Inc. | call | Sold out | 1,000 | $46Kbefore exit |
| ANAB Anaptysbio Inc. | call | New | 2,000 | $45K |
| ROIV Roivant Sciences Ltd. | call | Sold out | 4,000 | $45Kbefore exit |
| SLNO Soleno Therapeutics Inc. | put | Sold out | 1,100 | $44Kbefore exit |
| ALT Altimmune Inc. | put | Sold out | 3,900 | $44Kbefore exit |
| BBIO Bridgebio Pharma Inc. | put | New | 1,200 | $37K |
| GPCR Structure Therapeutics Inc. | call | New | 800 | $34K |
| ARVN Arvinas Inc. | put | Sold out | 800 | $33Kbefore exit |
| BCLI Brainstorm Cell Therapeutics | put | Sold out | 100,700 | $27Kbefore exit |
| EQ Equillium Inc. | call | New | 10,000 | $23K |
| EYPT Eyepoint Inc. | put | Sold out | 800 | $18Kbefore exit |
| AKBA Akebia Therapeutics Inc. | put | New | 9,700 | $18K |
| REVIVA PHARMACEUTCLS HLDGS I | put | Sold out | 2,500 | $13Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q4 2023 → Q1 2024
| NAMSW Newamsterdam Pharma Co. NV-27 | *W EXP 99/99/999 | Sold out | 82,857 | $259Kbefore exit |
| NUBIW Nubia Brand Intern -CW27 | *W EXP 11/16/202 | Sold out | 13,500 | $634before exit |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 260 | $2.1B | ABVX, PTGX, ROIV, SPY, IMVT |
| Q1 2026 | 290 | $1.6B | ABVX, PTGX, ROIV, IMVT, SPY |
| Q4 2025Amended | 248 | $1.3B | ABVX, PTGX, ROIV, IMVT, RNAM |
| Q3 2025 | 196 | $1.0B | ABVX, KROS, PTGX, ROIV, BOXX |
| Q2 2025 | 192 | $609.1M | KROS, PTGX, BOXX, ZLAB, ABVX |
| Q1 2025 | 185 | $505.1M | PTGX, BOXX, ROIV, ZLAB, IMVT |
| Q4 2024 | 185 | $469.3M | ROIV, PTGX, BOXX, ZLAB, IMVT |
| Q3 2024 | 244 | $596.5M | CYTK, PTGX, BBIO, BOXX, ROIV |
| Q2 2024 | 231 | $496.6M | PTGX, CYTK, ROIV, BOXX, BBIO |
| Q1 2024 | 223 | $366.2M | BOXX, ROIV, ALNY, PTGX, CYTK |